Gliomas are the most common central nervous system tumors. New technologies, including
genetic research and advanced statistical methods, revolutionize the therapeutic approach …

Oncology indispensably leads us to personalized medicine, which allows an individual
approach to be taken with each patient. Personalized oncology is based on …

Context.—The diagnosis and clinical management of patients with diffuse gliomas (DGs)
have evolved rapidly over the past decade with the emergence of molecular biomarkers that …

Introduction The accurate detection of genetic variants such as single substitutions (IDH1/2,
TERT), chromosomal abnormalities (CDKN2A, 1p/19q deletions, and EGFR amplifications) …

Simple Summary Pronounced differences across individuals (interpatient variability) and cell–
cell heterogeneity within a tumor (intratumoral heterogeneity) severely hinder effective brain …

Background IDH (Isocitrate dehydrogenase) mutations occur frequently in gliomas, but their
prognostic impact has not been fully assessed. We performed a meta-analysis of the …

Abstract Mutations of isocitrate dehydrogenase 1/2 (IDH1/2) have been reported in gliomas
and other types of tumors, such as acute myeloid leukemias, cartilaginous tumors …

WHO grade II diffuse low-grade gliomas (DLGGs) were recently divided into sub-groups on
the basis of their molecular profiles. IDH wild-type (IDH-wt) tumors seem to be associated …

Isocitrate dehydrogenase (IDH) is of great importance in cell metabolism and energy
conversion. IDH mutation in glioma cells is reported to be associated with an increased …

Following the first CNS Anticancer Drug Discovery and Development Conference, the
speakers from the first 4 sessions and organizers of the conference created this White Paper …